Sponsors appear to have got what they wanted in terms of disclosure requirements for the US FDA's complex innovative trial design (CID) pilot program, as they likely will not have to reveal certain information about their company or product if selected for the program.
The specific information disclosed to the public about each case study will depend on the content of each application, the...







